Overview

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety, tolerability and pharmacokinetic (PK) profile of AMG 386 after intravenous administration in adult subjects with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Trebananib